Literature DB >> 18953222

An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.

Sudeep Karve1, Mario A Cleves, Mark Helm, Teresa J Hudson, Donna S West, Bradley C Martin.   

Abstract

OBJECTIVE: To compare the predictive validity of 8 different adherence measures by studying the variability explained between each measure and 2 outcome measures: hospitalization episodes and total nonpharmacy cost among Medicaid eligible persons diagnosed with diabetes. RESEARCH
DESIGN: This study was a retrospective analysis of the Arkansas Medicaid administrative claims data from January 2000 to December 2006.
SUBJECTS: Diabetic (ICD-9-CM = 250.0 x - 250.9 x, where x = 0 or 2) patients were identified in the recruitment period July 2000 through April 2004. Patients had to be >or=18 years old and have at least 2 prescription fills in the index period for an oral antidiabetic drug. MEASURES: : Adherence rates to oral antidiabetic therapy were contrasted using the following 8 measures; including the medication possession ratio (MPR), proportion of days covered (PDC), refill compliance rate (RCR), compliance ratio (CR), medication possession ratio, modified (MPRm), continuous measure of medication gaps (CMG), and continuous multiple interval measure of oversupply (CMOS and continuous, single interval measure of medication acquisition (CSA). Multivariate and univariate linear and logistic regression models were used to prospectively predict nonpharmacy costs and hospitalizations in the follow-up year.
RESULTS: A total of 4943 diabetic patients were studied. In predicting any cause hospitalization, univariate models with PDC and CMG had the highest predictive validity (C-statistic: 0.544). Multivariate models with MPR, PDC, CMG or continuous multiple interval measure of oversupply (CMOS) as adherence measures had the highest C-statistics of 0.701 in predicting diabetes specific hospitalizations. None of the adherence measures were significantly associated with nonpharmacy cost.
CONCLUSIONS: MPR and PDC had the highest predictive validity for hospitalization episodes. These 2 measures should be considered first when selecting among adherence measures when using administrative prescription claims data.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953222     DOI: 10.1097/MLR.0b013e31817924d2

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  62 in total

1.  Methodological issues in the assessment of diabetes treatment adherence.

Authors:  Jeffrey S Gonzalez; Havah E Schneider
Journal:  Curr Diab Rep       Date:  2011-12       Impact factor: 4.810

2.  Observing versus Predicting: Initial Patterns of Filling Predict Long-Term Adherence More Accurately Than High-Dimensional Modeling Techniques.

Authors:  Jessica M Franklin; William H Shrank; Joyce Lii; Alexis K Krumme; Olga S Matlin; Troyen A Brennan; Niteesh K Choudhry
Journal:  Health Serv Res       Date:  2015-04-16       Impact factor: 3.402

3.  The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control.

Authors:  Lindsay S Mayberry; Jeffrey S Gonzalez; Kenneth A Wallston; Sunil Kripalani; Chandra Y Osborn
Journal:  Diabetes Res Clin Pract       Date:  2013-09-26       Impact factor: 5.602

4.  Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes.

Authors:  Marjolein M J Zanders; Harm R Haak; Myrthe P P van Herk-Sukel; Lonneke V van de Poll-Franse; Jeffrey A Johnson
Journal:  Diabetologia       Date:  2015-02-01       Impact factor: 10.122

Review 5.  Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.

Authors:  Elisabeth Lilian Pia Sattler; Jung Sun Lee; Matthew Perri
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

6.  Impact of Cardiovascular Risk Factors on Graft Outcome Disparities in Black Kidney Transplant Recipients.

Authors:  David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede
Journal:  Hypertension       Date:  2016-07-11       Impact factor: 10.190

7.  How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.

Authors:  Thomas Wilke; Antje Groth; Sabrina Mueller; Dallas Reese; Roland Linder; Susanne Ahrens; Frank Verheyen
Journal:  Eur J Health Econ       Date:  2012-07-20

8.  Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases.

Authors:  Margret V Bjarnadottir; David Czerwinski; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

9.  Aberrant Behaviors and Co-occurring Conditions as Predictors of Psychotropic Polypharmacy among Children with Autism Spectrum Disorders.

Authors:  Sarah L Logan; Laura Carpenter; R Scott Leslie; Elizabeth Garrett-Mayer; Kelly J Hunt; Jane Charles; Joyce S Nicholas
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

10.  Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice.

Authors:  Laurie J Pencille; Megan E Campbell; Holly K Van Houten; Nilay D Shah; Rebecca J Mullan; Brian A Swiglo; Maggie Breslin; Rebecca L Kesman; Sidna M Tulledge-Scheitel; Thomas M Jaeger; Ruth E Johnson; Gregory A Bartel; Robert A Wermers; L Joseph Melton; Victor M Montori
Journal:  Trials       Date:  2009-12-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.